Mutations in cancer genes and targetable genetic lesions in the post–allo-SCT relapses. (A) Mutated cancer genes across all patients and oncogenomes. (B) Details on those cancer genes, which were mutated in at least 2 patients. UPNs as earlier. (C) Targetable genes carrying mutations in the OG3 of the respective patients, with possible therapeutic options indicated. SNVs are indicated in red, copy number losses in orange, hypermutated oncogenomes (defined by ≥200 SNVs) in blue. (D) Sensitivity testing of patient cells/patient-derived xenografts against APR-246 in different concentrations (1-5-10-100 micro molar). neg. ctrl., negative control (primograft X116; TP53 wild-type); pos. ctrl., positive control (TP53 mutant primograft X172 carrying 2 TP53 mutations on different alleles).